lomerizine inn also known diphenylpiperazine class ltype ttype calcium channel drug currently used clinically treatment migraines also used experimentally treatment glaucoma optic nerve injury due lipophilic nature small molecular size lomerizine able cross blood brain barrier delivery aqueous systems nanoparticle therapy may along lipids lomerizine soluble chloroform methanol dmso lomerizine works calcium blocking voltagedependent calcium study using showed lomerizine allosterically inhibits binding calcium channels different site dihydropyridine binding however antimigraine effects believed due blocking calcium channels antagonizing effects lomerizine receptor drug shown competitively inhibit binding receptors inhibiting driven release lomerizine treatment expressing cells led inhibition release response release response atp preventing release lomerizine prevents serotonininduced contraction basilar artery lead migraines lomerizine also shown possess neuroprotective effects specifically case retinal damage doses mgkg given intravenously pretreatment shown prevent glutamateinduced neurotoxicity also providing protection nmdainduced kainateinduced neurotoxicity lomerizine shown little affinity nmda kainate receptors protectivity neurotoxicity cases believed due blocking influx voltagedependent calcium blocking channels preventing release lomerizine increases circulation optic nerve head effects show lomerizine may prove useful treatment ischemic retinal diseases lomerizine also shows neuroprotective effects secondary degeneration resulting injury retinal ganglion cells case increased membrane depolarization conjunction inability sodiumcalcium exchanger function due depleted atp stores causes activation calciumdependent signal transduction processes lead cell death either apoptosis lomerizines role blocking rescue cells death preventing excitotoxicity decreased intracellular calcium also prevents necrosis decreasing permeability apoptotic death reduced reduction calciumdependent apoptotic calciumchannel blockers flunarizine act dopaminergic system lomerizine ineffective vivo inhibiting release dopamine however observed weakly inhibit binding dopamine receptors researchers unsure reason difference one hypothesis doses administered reach high enough concentration brain affect lomerizine typically taken orally dose mg two three times doses mg also available intravenous solution lomerizine hydrochloride preferred route administration especially treatment optic nerve clinical study longterm lomerizine usage shown safe effective treatment migraines however efficacy drug decreases age significant correlation age efficacy preventing migraine efficacies reported gender seems effect efficacy drug lomerizine may cause drowsiness flushing lacks serious cardiovascular effects hypotension produced calcium antagonists hypothesized due drugs selectivity cerebral peripheral arteries side effects reported acute toxicity lomerizine mice found mgkg intravenously mgkg orally mgkg subcutaneously overdose result seizures convulsions toxicity humans administered intravenously rabbits dose mgkg drug reached average peak plasma concentration ngml preparation completely metabolised within minutes administered rats dose mgkg lomerizine reached cmax ngml tmax minutes guinea pig dog aortic membranes drug displaced binding calcium agonist nm ki administered orally healthy male subjects mg doses lomerizine produced peak plasma levels group healthy adults mg lomerizine administered orally halflife hours peak serum concentration cmax ngml tmax reported lomerizine reported nm bioavailability orally administered lomerizine unaffected gastric httpsenwikipediaorgwikilomerizine